Novo Nordisk buys blood drug licence to boost anaemic biopharma business
Epidestiny Heading link
Novo Nordisk, a Danish drugmaker, has secured the global license for Epidestiny’s sickle cell disease program. Epidestiny is a startup company that focuses on using Gene Control Therapy to improve human disease outcomes. They are utilizing research developed by UIC researcher Yogen Saunthararajah and group to specifically treat blood disorders such as Sickle Cell disease and Beta-Thalassemia. Click on the following link to learn more about this exciting venture.
Modified on April 12, 2019